MA46570B1 - Procédés et compositions pharmaceutiques permettant de favoriser la réaction des lymphocytes t - Google Patents

Procédés et compositions pharmaceutiques permettant de favoriser la réaction des lymphocytes t

Info

Publication number
MA46570B1
MA46570B1 MA46570A MA46570A MA46570B1 MA 46570 B1 MA46570 B1 MA 46570B1 MA 46570 A MA46570 A MA 46570A MA 46570 A MA46570 A MA 46570A MA 46570 B1 MA46570 B1 MA 46570B1
Authority
MA
Morocco
Prior art keywords
clec
promoting
methods
lymphocytes
reaction
Prior art date
Application number
MA46570A
Other languages
English (en)
French (fr)
Other versions
MA46570A (fr
Inventor
Nicolas Poirier
Bernard Vanhove
Vanessa Gauttier
Elise Chiffoleau
Géraldine TEPPAZ
Original Assignee
Ose Immunotherapeutics
Inst Nat Sante Rech Med
Univ Nantes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ose Immunotherapeutics, Inst Nat Sante Rech Med, Univ Nantes filed Critical Ose Immunotherapeutics
Publication of MA46570A publication Critical patent/MA46570A/fr
Publication of MA46570B1 publication Critical patent/MA46570B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4726—Lectins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1732—Lectins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/7056—Lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA46570A 2016-10-21 2017-10-20 Procédés et compositions pharmaceutiques permettant de favoriser la réaction des lymphocytes t MA46570B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16306381 2016-10-21
EP17305988 2017-07-24
PCT/EP2017/076911 WO2018073440A1 (en) 2016-10-21 2017-10-20 Methods for promoting t cells response

Publications (2)

Publication Number Publication Date
MA46570A MA46570A (fr) 2021-03-31
MA46570B1 true MA46570B1 (fr) 2021-10-29

Family

ID=60293924

Family Applications (1)

Application Number Title Priority Date Filing Date
MA46570A MA46570B1 (fr) 2016-10-21 2017-10-20 Procédés et compositions pharmaceutiques permettant de favoriser la réaction des lymphocytes t

Country Status (21)

Country Link
US (3) US11365257B2 (OSRAM)
EP (2) EP3529262B1 (OSRAM)
JP (2) JP7032396B6 (OSRAM)
KR (1) KR102646708B1 (OSRAM)
CN (1) CN110291102A (OSRAM)
AU (1) AU2017345286B2 (OSRAM)
CA (1) CA3039348C (OSRAM)
CY (1) CY1124584T1 (OSRAM)
DK (1) DK3529262T3 (OSRAM)
ES (2) ES2883678T3 (OSRAM)
HR (1) HRP20211544T1 (OSRAM)
HU (1) HUE056016T2 (OSRAM)
IL (1) IL266111B (OSRAM)
LT (1) LT3529262T (OSRAM)
MA (1) MA46570B1 (OSRAM)
MD (1) MD3529262T2 (OSRAM)
PL (1) PL3529262T3 (OSRAM)
RS (1) RS62463B1 (OSRAM)
SI (1) SI3529262T1 (OSRAM)
SM (1) SMT202100555T1 (OSRAM)
WO (1) WO2018073440A1 (OSRAM)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102646708B1 (ko) * 2016-10-21 2024-03-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) T 세포 반응을 촉진하는 방법
BR112019017751A2 (pt) 2017-02-28 2020-04-07 Vor Biopharma, Inc. composições e métodos de inibição de proteínas de linhagem específica
CN113423725A (zh) 2018-08-28 2021-09-21 Vor生物制药股份有限公司 遗传工程化造血干细胞及其用途
US20230331852A1 (en) * 2019-12-05 2023-10-19 Ose Immunotherapeutics Anti-clec-1a antibodies and antigen-binding fragment thereof
CN113156140A (zh) * 2021-03-05 2021-07-23 青岛大学附属医院 C型凝集素样受体-1作为真菌性角膜炎的治疗标志物的应用
JP7753401B2 (ja) * 2021-06-08 2025-10-14 オーエスイー・イミュノセラピューティクス ヒト化抗ｃｌｅｃ－１ａ抗体及びその抗原結合断片及びそのミメティック
JP2024542409A (ja) 2021-11-09 2024-11-15 オーエスイー・イミュノセラピューティクス Ｃｌｅｃ－１リガンドの同定及びその使用
WO2024028347A1 (en) 2022-08-01 2024-02-08 Ose Immunotherapeutics Heterodimeric fc-clec-1 fusion molecule and uses thereof
WO2025032213A1 (en) 2023-08-10 2025-02-13 Ose Immunotherapeutics Identification of hla-dra as a ligand of clec-1 and uses thereof

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
ATE452975T1 (de) 1992-08-21 2010-01-15 Univ Bruxelles Immunoglobuline ohne leichte ketten
US5618829A (en) 1993-01-28 1997-04-08 Mitsubishi Chemical Corporation Tyrosine kinase inhibitors and benzoylacrylamide derivatives
WO1995002420A2 (en) 1993-07-15 1995-01-26 Cancer Research Campaign Technology Ltd. Prodrugs of protein tyrosine kinase inhibitors
EP0690452A3 (en) 1994-06-28 1999-01-07 Advanced Micro Devices, Inc. Electrically erasable memory and method of erasure
US5804396A (en) 1994-10-12 1998-09-08 Sugen, Inc. Assay for agents active in proliferative disorders
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
US5639757A (en) 1995-05-23 1997-06-17 Pfizer Inc. 4-aminopyrrolo[2,3-d]pyrimidines as tyrosine kinase inhibitors
RO121900B1 (ro) 1996-04-12 2008-07-30 Warner-Lambert Company Compuşi inhibitori, ireversibili, ai tirozin kinazelor, compoziţie farmaceutică care îi conţine şi utilizarea acestora
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
US6100254A (en) 1997-10-10 2000-08-08 Board Of Regents, The University Of Texas System Inhibitors of protein tyrosine kinases
US6740665B1 (en) 1999-02-10 2004-05-25 Ramachandran Murali Tyrosine kinase inhibitors and methods of using the same
US6245759B1 (en) 1999-03-11 2001-06-12 Merck & Co., Inc. Tyrosine kinase inhibitors
US6316444B1 (en) 1999-06-30 2001-11-13 Merck & Co., Inc. SRC kinase inhibitor compounds
ATE253915T1 (de) 1999-06-30 2003-11-15 Merck & Co Inc Src-kinase hemmende verbindungen
JP2003503351A (ja) 1999-06-30 2003-01-28 メルク エンド カムパニー インコーポレーテッド Ｓｒｃキナーゼ阻害化合物
ATE309241T1 (de) 1999-09-10 2005-11-15 Merck & Co Inc Tyrosin kinase inhibitoren
DE60018782T2 (de) 1999-10-19 2006-04-06 Merck & Co., Inc. Tyrosin kinase inhibitoren
BR0014843A (pt) 1999-10-19 2002-06-11 Merck & Co Inc Composto, composição farmacêutica, métodos para tratar ou prevenir o câncer em um mamìfero, uma doença em que a angiogênese está implicada, a vascularização retinal, a retinipatia diabética, a degeneração macular relacionada com a idade, doença inflamatória, uma doença ou condição dependente de tirosina quinase e, patologias relacionadas com o osso, processo para fabricar uma composição farmacêutica, e, método para reduzir ou impedir o dano de tecido que segue um evento isquêmico
US6794393B1 (en) 1999-10-19 2004-09-21 Merck & Co., Inc. Tyrosine kinase inhibitors
AU785198B2 (en) * 1999-11-15 2006-11-02 Miltenyi Biotec B.V. & Co. KG Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognised thereby and cells obtained thereby
US6313138B1 (en) 2000-02-25 2001-11-06 Merck & Co., Inc. Tyrosine kinase inhibitors
US6420382B2 (en) 2000-02-25 2002-07-16 Merck & Co., Inc. Tyrosine kinase inhibitors
CA2450562A1 (en) 2001-06-22 2003-01-03 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2003011836A1 (en) 2001-08-01 2003-02-13 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2003020276A1 (en) 2001-08-30 2003-03-13 Merck & Co., Inc. Tyrosine kinase inhibitors
US8246959B1 (en) * 2003-08-01 2012-08-21 University Of Washington Dendritic cell-associated lectin-like molecules, compositions and methods of use
US7908091B2 (en) 2006-03-17 2011-03-15 Prometheus Laboratories Inc. Methods of predicting and monitoring tyrosine kinase inhibitor therapy
KR20090118981A (ko) * 2007-02-23 2009-11-18 베일러 리서치 인스티튜트 Ｃｌｅｃ-6을 통한 사람 항원제시세포의 활성화
JP5641508B2 (ja) * 2010-02-23 2014-12-17 国立大学法人 東京大学 樹状細胞免疫受容体刺激剤
WO2016014535A1 (en) * 2014-07-21 2016-01-28 Novartis Ag Treatment of cancer using a cll-1 chimeric antigen receptor
KR102646708B1 (ko) 2016-10-21 2024-03-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) T 세포 반응을 촉진하는 방법

Also Published As

Publication number Publication date
JP7404418B6 (ja) 2024-01-26
AU2017345286B2 (en) 2023-08-03
SMT202100555T1 (it) 2021-11-12
JP2020503252A (ja) 2020-01-30
DK3529262T3 (da) 2021-09-20
JP2022065159A (ja) 2022-04-26
KR102646708B1 (ko) 2024-03-12
ES2883678T3 (es) 2021-12-09
WO2018073440A1 (en) 2018-04-26
HRP20211544T1 (hr) 2022-01-07
JP7404418B2 (ja) 2023-12-25
MD3529262T2 (ro) 2022-01-31
US20240400695A1 (en) 2024-12-05
HUE056016T2 (hu) 2022-01-28
JP7032396B2 (ja) 2022-03-08
IL266111B (en) 2022-09-01
IL266111A (en) 2019-06-30
CY1124584T1 (el) 2022-07-22
MA46570A (fr) 2021-03-31
US20190309075A1 (en) 2019-10-10
EP3529262B1 (en) 2021-07-21
JP7032396B6 (ja) 2022-03-22
PL3529262T3 (pl) 2021-12-27
SI3529262T1 (sl) 2021-12-31
KR20190068605A (ko) 2019-06-18
CA3039348C (en) 2023-09-05
US20220281983A1 (en) 2022-09-08
AU2017345286A1 (en) 2019-04-18
ES2978486T3 (es) 2024-09-13
US12091464B2 (en) 2024-09-17
EP3950709B1 (en) 2024-02-14
CA3039348A1 (en) 2018-04-26
EP3529262A1 (en) 2019-08-28
EP3950709A1 (en) 2022-02-09
CN110291102A (zh) 2019-09-27
RS62463B1 (sr) 2021-11-30
LT3529262T (lt) 2021-11-10
US11365257B2 (en) 2022-06-21

Similar Documents

Publication Publication Date Title
MA46570B1 (fr) Procédés et compositions pharmaceutiques permettant de favoriser la réaction des lymphocytes t
Culley et al. Natural killer cell signal integration balances synapse symmetry and migration
Sun et al. mTOR complex 1 signaling regulates the generation and function of central and effector Foxp3+ regulatory T cells
Tennakoon et al. Therapeutic induction of regulatory, cytotoxic CD8+ T cells in multiple sclerosis
Ritzel et al. Age-associated resident memory CD8 T cells in the central nervous system are primed to potentiate inflammation after ischemic brain injury
Akimova et al. Helios expression is a marker of T cell activation and proliferation
Le Rond et al. Evidence to support the role of HLA-G5 in allograft acceptance through induction of immunosuppressive/regulatory T cells
Marko et al. Age-associated decline in effective immune synapse formation of CD4+ T cells is reversed by vitamin E supplementation
Li et al. Cutting Edge: mechanical forces acting on T cells immobilized via the TCR complex can trigger TCR signaling
Meuth et al. Cytotoxic CD8+ T cell–neuron interactions: perforin-dependent electrical silencing precedes but is not causally linked to neuronal cell death
Soares et al. Regulated vesicle fusion generates signaling nanoterritories that control T cell activation at the immunological synapse
Whitmire et al. Precursor frequency, nonlinear proliferation, and functional maturation of virus-specific CD4+ T cells
Marcel et al. Notch1 regulated autophagy controls survival and suppressor activity of activated murine T-regulatory cells
Campese et al. Mouse Sertoli cells sustain de novo generation of regulatory T cells by triggering the notch pathway through soluble JAGGED1
Do et al. Nutrient mTORC1 signaling underpins regulatory T cell control of immune tolerance
Casado et al. CD8 T cells expressing NK associated receptors are increased in melanoma patients and display an effector phenotype
Harper et al. Dynamic resolution of acrosomal exocytosis in human sperm
Duong et al. Chronic TCR-MHC (self)-interactions limit the functional potential of TCR affinity-increased CD8 T lymphocytes
Brant et al. Role of the aryl hydrocarbon receptor in the immune response profile and development of pathology during Plasmodium berghei Anka infection
Sharma et al. LFA-1 ligation by high-density ICAM-1 is sufficient to activate IFN-γ release by innate T lymphocytes
Babad et al. Generation of β cell-specific human cytotoxic T cells by lentiviral transduction and their survival in immunodeficient human leucocyte antigen-transgenic mice
Lucas et al. Control of the thymic medulla and its influence on αβT‐cell development
Schuldt et al. Cutting edge: Dual TCRα expression poses an autoimmune hazard by limiting regulatory T cell generation
Thedrez et al. CD4 engagement by CD1d potentiates activation of CD4+ invariant NKT cells
Choe et al. In vivo high spatiotemporal resolution visualization of circulating T lymphocytes in high endothelial venules of lymph nodes